JP2018528242A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528242A5
JP2018528242A5 JP2018515619A JP2018515619A JP2018528242A5 JP 2018528242 A5 JP2018528242 A5 JP 2018528242A5 JP 2018515619 A JP2018515619 A JP 2018515619A JP 2018515619 A JP2018515619 A JP 2018515619A JP 2018528242 A5 JP2018528242 A5 JP 2018528242A5
Authority
JP
Japan
Prior art keywords
formulation
aprotic solvent
ionization
glucagon peptide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528242A (ja
JP6835831B2 (ja
Filing date
Publication date
Priority claimed from US15/136,650 external-priority patent/US9649364B2/en
Application filed filed Critical
Publication of JP2018528242A publication Critical patent/JP2018528242A/ja
Publication of JP2018528242A5 publication Critical patent/JP2018528242A5/ja
Application granted granted Critical
Publication of JP6835831B2 publication Critical patent/JP6835831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515619A 2015-09-25 2016-09-25 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 Active JP6835831B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562233032P 2015-09-25 2015-09-25
US62/233,032 2015-09-25
US15/136,650 2016-04-22
US15/136,650 US9649364B2 (en) 2015-09-25 2016-04-22 Methods for producing stable therapeutic formulations in aprotic polar solvents
PCT/US2016/053628 WO2017053922A1 (en) 2015-09-25 2016-09-25 Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Publications (3)

Publication Number Publication Date
JP2018528242A JP2018528242A (ja) 2018-09-27
JP2018528242A5 true JP2018528242A5 (https=) 2019-09-12
JP6835831B2 JP6835831B2 (ja) 2021-02-24

Family

ID=57113760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515619A Active JP6835831B2 (ja) 2015-09-25 2016-09-25 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法

Country Status (17)

Country Link
US (6) US9649364B2 (https=)
EP (2) EP4327804B1 (https=)
JP (1) JP6835831B2 (https=)
KR (2) KR102662530B1 (https=)
CN (2) CN115531523A (https=)
AU (1) AU2016326749B2 (https=)
CA (2) CA2999404C (https=)
DK (2) DK4327804T3 (https=)
EA (1) EA201890704A1 (https=)
ES (2) ES3055702T3 (https=)
IL (1) IL258298B (https=)
MX (1) MX2018003705A (https=)
PL (1) PL4327804T3 (https=)
PT (1) PT4327804T (https=)
SA (1) SA518391187B1 (https=)
WO (1) WO2017053922A1 (https=)
ZA (2) ZA201801912B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
BR112020000447A2 (pt) 2017-07-14 2020-07-21 Xeris Pharmaceuticals, Inc. métodos de tratamento de hiperinsulinismo congênito
MX2020006658A (es) * 2017-12-22 2020-11-06 Xeris Pharmaceuticals Inc Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina.
US20210030847A1 (en) * 2018-01-23 2021-02-04 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
EP3761962A4 (en) * 2018-03-07 2021-12-15 ReForm Biologics, Inc. EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
KR20220024061A (ko) * 2019-05-31 2022-03-03 엑스에리스 파머수티클스, 인크. 비양성자성 극성 용매 중의 안정한 치료 조성물 및 이의 제조 방법
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法
CN115916153A (zh) 2020-06-26 2023-04-04 Xeris药物公司 非质子极性溶剂中的稳定缓释治疗性组合物及其制备方法
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon
JP2025535354A (ja) 2022-10-19 2025-10-24 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定なレボチロキシン組成物
KR20250103637A (ko) 2022-10-19 2025-07-07 엑스에리스 파머수티클스, 인크. 비양성자성 극성 용매를 사용한 서방형 주사용 제형
WO2025184608A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of an amylin analog and uses thereof
WO2025184589A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of glucagon-like peptide-1 receptor agonists and uses thereof

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016895A (en) 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
GB2119248A (en) 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
CH664005A5 (de) 1984-05-19 1988-01-29 Glatt Maschinen & Apparatebau Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens.
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4848094A (en) 1988-04-29 1989-07-18 Union Carbide Corporation Droplet freezing method and apparatus
US5031336A (en) 1989-08-31 1991-07-16 Abbott Laboratories Lyophilization of bulk pharmaceuticals
US5092843A (en) 1990-04-12 1992-03-03 Survival Technology, Inc. Dispersion multichamber auto-injector
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5208998A (en) 1991-02-25 1993-05-11 Oyler Jr James R Liquid substances freeze-drying systems and methods
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ES2115201T3 (es) 1992-12-15 1998-06-16 Sanofi Sa Dispositivo para la preparacion de una solucion, de una suspension o de una emulsion de una sustancia medicinal.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
NZ292980A (en) 1994-09-29 1999-02-25 Andaris Ltd Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5945128A (en) 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
AU5719798A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
EP1285667B1 (en) 1997-11-18 2006-06-14 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmaceutical injectable solution of paracetamol and combinations of paracetamol with other active substances
FR2783433B1 (fr) 1998-09-18 2001-02-16 Delab Seringues pour l'administration de formulations pateuses ou semi-solides
SE9803662D0 (sv) 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
US6199297B1 (en) 1999-02-01 2001-03-13 Integrated Biosystems, Inc. Lyophilization apparatus and methods
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
EP1187602A4 (en) 2000-04-18 2004-09-15 Peptron Inc SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
NZ523385A (en) 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
EP1310252A4 (en) 2000-08-18 2009-06-10 Takeda Pharmaceutical INJECTIONS
RO120121B1 (ro) 2000-12-18 2005-09-30 Elena Ionaşcu Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
US8166969B2 (en) 2001-03-06 2012-05-01 Texas Research International, Inc. Chemically and biologically resistant hydration system
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
EP1411861B1 (en) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
US20040142043A1 (en) 2001-07-09 2004-07-22 Atsushi Maeda Sustained-release compositions for injection and process for producing the same
US6733813B2 (en) 2001-08-02 2004-05-11 Ocean Spray Cranberries, Inc. Process for producing acids-enriched juice and acids-reduced juice
DE60239952D1 (de) 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
EA006939B1 (ru) 2001-12-18 2006-06-30 Юни-Фарма Клеон Цетис Фармасьютикал Лэборетериз С. А. Парентеральная композиция парацетамола
CN1171610C (zh) 2002-04-23 2004-10-20 张瑞香 一种治疗心脑血管和眼底病的中药针剂及其制备方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
EP1554304B1 (en) 2002-10-17 2009-06-10 The University Of British Columbia Ship 1 modulators
EP1558234B1 (en) 2002-10-25 2007-05-23 Dompé S.P.A. Painless injectable compositions containing salt of 2-arylpropionic acids
MXPA05006670A (es) 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
CN1507858A (zh) 2002-12-19 2004-06-30 王玉万 含氟化氯霉素的兽用液体制剂
CA2510196C (en) 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
AU2003230899A1 (en) 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
DK1468697T3 (da) 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion
KR100517643B1 (ko) 2003-07-25 2005-09-28 한국과학기술연구원 온도 감응성 폴리포스파젠계 고분자, 이의 제조방법 및이를 이용한 주입형 온도 감응성 폴리포스파젠 하이드로젤
US20050100538A1 (en) 2003-07-31 2005-05-12 Attawia Mohamed Intradiscal injection of anti-oxidants
SI1502589T1 (sl) 2003-07-31 2006-12-31 Emdoka Bvba Drug Registration Veterinarske vodne injektibilne suspenzije, ki vsebujejo florfenikol
JP4777067B2 (ja) 2003-08-22 2011-09-21 ジングルス・テヒノロギース・アクチェンゲゼルシャフト ディスク状基板の結合のための方法およびこの方法を実行するための装置
CN1856296A (zh) 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20080145383A1 (en) 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
US20050240166A1 (en) 2004-04-26 2005-10-27 Microsolutions, Inc. Implantable device, formulation and method for anti-psychotic therapy using risperidone
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US20060160823A1 (en) 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
CA2580264A1 (en) 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
AU2006208108A1 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including NDGA compounds
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP2018883A4 (en) 2006-05-17 2009-05-13 Terumo Corp indwelling
WO2007140312A2 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
EP2063869B1 (en) 2006-09-07 2014-03-05 Merial Ltd. Soft chewable veterinary antibiotic formulations
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
WO2008098212A2 (en) 2007-02-08 2008-08-14 Diobex, Inc. Extended release formulations of glucagon and other peptides and proteins
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP2010525033A (ja) 2007-04-30 2010-07-22 ノボ・ノルデイスク・エー/エス 高濃縮のインスリン溶液及び組成物
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー/エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101842079B (zh) 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
US20090088393A1 (en) 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
CA2731353A1 (en) 2008-07-23 2010-02-18 Bharat Serums & Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
AU2009285115A1 (en) 2008-08-25 2010-03-04 Denki Kagaku Kogyo Kabushiki Kaisha Syringe
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110118578A1 (en) 2009-11-17 2011-05-19 Roche Diagnostics Operations, Inc. Hypoglycemic treatment methods and systems
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
JP5632226B2 (ja) 2010-07-30 2014-11-26 株式会社細川洋行 医療用多層チューブ、および医療用輸液バッグ
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
AU2013308693A1 (en) 2012-08-29 2015-03-12 Mannkind Corporation Method and composition for treating hyperglycemia
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
KR102327754B1 (ko) 2014-02-06 2021-11-17 엑스에리스 파머수티클스, 인크. 안정한 펩티드 제형물 및 제조 방법
WO2015153728A1 (en) 2014-04-02 2015-10-08 Xeris Pharmaceuticals, Inc. Polar aprotic solvent-compatible infusion sets, components, and methods

Similar Documents

Publication Publication Date Title
JP2018528242A5 (https=)
JP6835831B2 (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2014507484A5 (https=)
BR112013023062B1 (pt) Solução estável para a injeção parenteral e método de fabricação da mesma
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
JP6882538B2 (ja) 注射用組成物
JP2017514868A5 (https=)
JP2017516848A5 (https=)
JP2016503058A5 (https=)
JP2017514924A5 (https=)
WO2015190378A1 (ja) 安定なアダリムマブ水性製剤
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
UY37550A (es) Nueva formulación que comprende un derivado de bencimidazol
ES3002132T3 (en) Lyophilized pharmaceutical composition of fc-peptide fusion protein
JP2021511386A5 (https=)
JP2021527084A5 (https=)
JP2022533759A5 (https=)
JP2016507535A5 (https=)
US12115164B2 (en) Pemetrexed formulations
TW202304426A (zh) 用於注射之包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的新調配物
JPWO2017179683A1 (ja) ミカファンギンの安定化された医薬組成物
AU2019228913C1 (en) Pharmaceutical composition with excellent storage stability
CA2969303A1 (en) Injectable formulations of paracetamol
RU2829138C2 (ru) Новый состав для инъекций, включающий 1-(5-(2,4-дифторфенил)-1-((3-фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамин
WO2015056613A1 (ja) 安定化されたポリペプチド水性製剤